BrainStorm Therapeutics
June 22, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
BrainStorm Therapeutics is an AI-powered precision neuroscience startup transforming drug discovery for brain diseases by combining patient iPS cell-derived brain organoids with advanced machine learning. Our platform enables functional modeling of neurological diseases in human neural tissue, allowing us to run “clinical trials in a dish” that generate predictive, human-relevant data. This approach addresses a major challenge in neuroscience, the high clinical failure rate driven by poor translatability of traditional models. Using our platform, we accelerate target discovery, validate therapeutic hypotheses, and screen drugs directly in patient-specific systems. Our technology has enabled the advancement of an IND-cleared Phase 2 program in a rare genetic epilepsy, discovered through phenotypic screening in cortical organoids. We are building a scalable engine for drug discovery across brain disorders, partnering with biopharma and investors to redefine how therapies are developed.
Company HQ City:
San Diego
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
Donepezil for Rett syndrome (IND-cleared for Phase II clinical trial)
CEO
Robert T. Fremeau, Jr., Ph.D.
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3 (AI-inferred Parkinson’s disease targets; hit-stage programs in Rett syndrome and CDKL5 deficiency disorder)
When you expect your next catalyst update?
December 2026
What is your next catalyst (value inflection) update?
Our next key value inflection point is the advancement of our AI-inferred Parkinson’s disease program through target validation and into hit identification, alongside continued progress in hit-to-lead development for Rett syndrome and CDKL5 deficiency disorder. In parallel, we expect to generate additional human-relevant data from our organoid platform to support partnerships and demonstrate translational predictivity, as well as potential collaboration or financing milestones that further validate and scale our platform.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}